MedCity News reports that about 15% of patients who take their daily aspirin, as prescribed by their physician’s, have gastrointestinal problems as a result. That’s 3.6 million patients who need to seek an alternative to help them be adherent for the purposes of fending off cardiovascular disease.
A NASDAQ listed company, called Pozen, has developed a drug that has been studied in two double blind tests over two years and involved over 1,000 subjects.

The company says it’s looking for a larger drug distribution company to partner on this drug, which they describe as not having a big price tag.  The FDA will likely review the drug for approval in early 2013.

Trusted by some of the biggest brands


We’re Waiting To Help You

Get in touch with us today and let’s start transforming your business from the ground up.